Skip to content
value.today
iBio, Inc. logo

iBio, Inc.

🇺🇸 Newark, Delaware, USABiotechnologyFounded 2008

Formerly iBioPharma, Inc., InB:Biotechnologies, Inc.

Total raised
$10 M
2 rounds on record
Latest round
$7 M
Oct 2010
First round on record
Sep 2009
Today
Went public
See the company page

iBio, Inc. is listed today as iBio, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of iBio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2026$26 MPrivate placement after listing$10 to $50 million

iBio, Inc.: Private sale, Jan 2026

Investors in this round

7 investors had bought by the notice of Jan 22, 2026: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,560,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Felipe A. Duran · Executive Officer
  • Marc A. Banjak · Executive Officer
  • Martin A. Brenner · Executive Officer, Director
  • Alexandra A. Kropotova · Director
  • Antonio A. Parada · Director
  • David A. Arkowitz · Director
  • Evert A. Shimmelpennink · Director
  • Gary A. Sender · Director
  • William A. Clark · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Oppenheimer & Co. Inc. (CRD 000000249) · New York, New YorkSold in CA, CT, IL, MA, NY
  • LifeSci Capital LLC (CRD 000168404) · New York, New YorkSold in CA, CT, IL, MA, NY
  • Leerink Partners LLC (CRD 000039011) · Boston, MassachusettsSold in CA, CT, IL, MA, NY

Remarks in the notice

  • On fees: “The total sales commission will be divided among the three placement agents as follows: 75% to Leerink Partners LLC, 12.5% to LifeSci Capital LLC and 12.5% to Oppenheimer & Co. Inc.”
  • On the amounts: “Does not include the proceeds to be received upon the cash exercise of pre-funded warrants issued in the private placement at an exercise price of $0.001 per share.”
  • On the use of proceeds: “While no offering proceeds are set aside for payments to named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”

Signed by Marc Banjak, Chief Legal Officer. Source: SEC Form D, newest notice filed Jan 22, 2026. Read the notice at the SEC.

optionsSEC
Apr 2025$11 MPrivate placement after listing$10 to $50 million

iBio, Inc.: Private sale, Apr 2025

Investors in this round

5 investors had bought by the notice of May 7, 2025: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$217,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Felipe A. Duran · Executive Officer
  • Marc A. Banjak · Executive Officer
  • Martin A. Brenner · Executive Officer, Director
  • Alexandra A. Kroptova · Director
  • Antonio A. Parada · Director
  • David A. Arkowitz · Director
  • Evert A. Shimmelpennink · Director
  • Gary A. Sender · Director
  • William A. Clark · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Chardan Capital Markets LLC (CRD 000120128) · New York, New YorkSold in GA, MA, NY, PR, TX

Remarks in the notice

  • On the amounts: “Includes $0.125 per share received upon sale of warrants and $0.86 per share that may be received upon future exercise of warrants”
  • On the use of proceeds: “While no offering proceeds are set aside for payments to named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”

Signed by Marc Banjak, Chief Legal Officer. Source: SEC Form D, newest notice filed May 7, 2025. Read the notice at the SEC.

optionsSEC
Mar 2024$15 MPrivate placement after listing$10 to $50 million

iBio, Inc.: Private sale, Mar 2024

Investors in this round

8 investors had bought by the notice of Apr 4, 2024: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Warrants and Pre-Funded Warrants
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$794,124
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Felipe Duran · Executive Officer
  • Martin Brenner · Executive Officer
  • Alexandra Kropotova · Director
  • Evert Shimmelpennink · Director
  • Gary Sende · Director
  • James Hill · Director
  • Linda Armstrong · Director
  • William Clark · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Chardan Capital Markets LLC (CRD 000120128) · New York, New YorkSold in GA, MA, NY, PR, TX

Remarks in the notice

  • On the use of proceeds: “While no offering proceeds are set aside for payments to named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”

Signed by Martin Brenner, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 4, 2024. Read the notice at the SEC.

equity, optionsSEC
Jan 2016$2 MPrivate placement after listing$2 to $10 million

iBio, Inc.: Private sale, Jan 2016

Investors in this round

1 investor had bought by the notice of Feb 3, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Giannone · Executive Officer · Chief Financial Officer
  • Robert Erwin · Executive Officer · President
  • Robert Kay · Executive Officer · Executive Chairman and Chief Executive Officer
  • Terence Ryan · Executive Officer · Chief Scientific Officer
  • Arthur Elliott · Director
  • Glenn Chang · Director
  • James Hill · Director
  • John McKey · Director
  • Philip Russell · Director
  • Seymour Flug · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert B. Kay, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 3, 2016. Read the notice at the SEC.

equitySEC
Oct 2010$7 MNo. 2$2 to $10 million

iBio, Inc.: Raise no. 2, Oct 2010

Investors in this round

52 investors had bought by the notice of Nov 10, 2010: 51 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $8 M offered; $1 M still to sell
Smallest investment taken
$5,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$560,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Frederick Larcombe · Executive Officer · Chief Financial Officer
  • Robert Kay · Director, Executive Officer · Chief Executive Officer
  • Glenn Chang · Director
  • JOHN McKEY · Director
  • James Hill · Director
  • Pamela K. Bassett · Director
  • Philip K. Russell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Noble International Investments, Inc. (CRD 15768) · Boca Raton, FloridaSold in FL, GA, IL, MD, NC, NY, SC, VA

Remarks in the notice

  • On fees: “Sales commissions of 7% shall be paid to the Placement Agent. To date, the Placement Agent has been paid $494,550.”

Signed by Robert B. Kay, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 10, 2010. Read the notice at the SEC.

equity, optionsSEC
Sep 2009$3 MNo. 1$2 to $10 million

iBio, Inc.: Raise no. 1, Sep 2009

Investors in this round

26 investors had bought by the notice of Sep 23, 2009: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$159,381
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Frederick Larcombe · Executive Officer
  • Geoffrey Schild · Executive Officer
  • Robert Erwin · Executive Officer
  • Robert Kay · Executive Officer, Director
  • Glenn Chang · Director
  • James T. Hill · Director
  • John D Mckey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Noble Financial Capital Markets (CRD 15768) · Boca Raton, FlSold in all US states

Signed by Frederick Larcombe, Cfo. Source: SEC Form D, newest notice filed Sep 23, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company iBio, Inc., its revenue in fiscal 2026 came from these product and service lines: Collaborative Revenues $100,000 (100%).

    Annual report (SEC XBRL) · Jun 2026

  • iBio, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2026).

    SEC Form D · Jan 2026

  • Revenue range over time, as stated in its notices: no revenue in 2010; revenue between $1 million and $5 million in 2016.

    SEC Form D (revenue range) · Feb 2016

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2026

Products and services#

No products or services of iBio, Inc. are on record.

Investors#

No investor of iBio, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 52 investors.

Largest shareholders today

Institutions holding iBio, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by iBio, Inc.
NameRoleNamed in
Felipe A. DuranExecutive officerJan 2026
Marc A. BanjakExecutive officerJan 2026
Martin A. BrennerExecutive officerJan 2026
Felipe DuranExecutive officerApr 2024
Martin BrennerExecutive officerApr 2024
Mark GiannoneChief Financial OfficerFeb 2016
Robert ErwinPresidentFeb 2016
Robert KayExecutive Chairman and Chief Executive OfficerFeb 2016
Terence RyanChief Scientific OfficerFeb 2016
Frederick LarcombeChief Financial OfficerNov 2010
Geoffrey SchildExecutive officerSep 2009
Alexandra A. KropotovaDirectorJan 2026
Antonio A. ParadaDirectorJan 2026
David A. ArkowitzDirectorJan 2026
Evert A. ShimmelpenninkDirectorJan 2026
Gary A. SenderDirectorJan 2026
Martin A. BrennerDirectorJan 2026
William A. ClarkDirectorJan 2026
Alexandra A. KroptovaDirectorMay 2025
Alexandra KropotovaDirectorApr 2024
Evert ShimmelpenninkDirectorApr 2024
Gary SendeDirectorApr 2024
James HillDirectorApr 2024
Linda ArmstrongDirectorApr 2024
William ClarkDirectorApr 2024
Arthur ElliottDirectorFeb 2016
Glenn ChangDirectorFeb 2016
John McKeyDirectorFeb 2016
Philip RussellDirectorFeb 2016
Seymour FlugDirectorFeb 2016
JOHN McKEYDirectorNov 2010
Pamela K. BassettDirectorNov 2010
Philip K. RussellDirectorNov 2010
Robert KayChief Executive OfficerNov 2010
James T. HillDirectorSep 2009
John D MckeyDirectorSep 2009

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.